Further molecular mechanisms and in vivo animal model studies are required to more comprehensively evaluate the efficacy and safety of CypA inhibitors as potential therapeutic agents for overcoming the chemoresistance and recurrence of GC. Here, PPIA is linked to gastric cancer.